Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Bilibili Inc (BILI) Price & Performance

Adaptive Biotechnologies CorpTrade
Bilibili IncTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Bilibili Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Bilibili Inc trades at $17.6 (market cap $7.65B). The key difference: Bilibili Inc is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Bilibili Inc nearer its low. Which is the better fit depends on your goals.

ADPTBILI
Market Cap
$4.04B$7.65B
Sector
HealthMedia
52-Week High
$25.45$35.92
52-Week Low
$12.30$15.96
Enterprise Value
$4.10B$5.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.

The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.

Bilibili Inc

Bilibili (BILI) trades at $17.61, down 7.27% over 24 hours, reflecting bearish technical signals despite strong analyst support. The company reported Q1 2026 EPS of $0.19, beating expectations, with revenue growth projected to $30.8B in 2026. Profit margins improved to 4.58%, though valuation ratios like P/E of 36.24 remain elevated. Recent news highlights a $300 million share repurchase program and upcoming Q2 earnings on August 27, 2026.

The outlook is mixed: bullish fundamentals from earnings beats and buy-side consensus contrast with near-term technical weakness. Key opportunities include user monetization and AI integration, while risks involve competitive pressure and reliance on Chinese market dynamics. The stock's trajectory hinges on Q2 results delivering sustained margin expansion.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Bilibili Inc

Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.

Read more on BILI